Qifeng Yang

List of Publications by Year
in descending order

66 papers	3,450 citations	201674 27 h-index	144013 57 g-index
66 all docs	66 docs citations	66 times ranked	5078 citing authors

#	Article	IF	Citations
1	Exosomal non-coding RNAs: Emerging roles in bilateral communication between cancer cells and macrophages. Molecular Therapy, 2022, 30, 1036-1053.	8.2	8
2	MTDH Promotes Intestinal Inflammation by Positively Regulating TLR Signalling. Journal of Crohn's and Colitis, 2021, 15, 2103-2117.	1.3	15
3	A High Epigenetic Risk Score Shapes the Non-Inflamed Tumor Microenvironment in Breast Cancer. Frontiers in Molecular Biosciences, 2021, 8, 675198.	3.5	1
4	A novel long non-coding RNA AC073352.1 promotes metastasis and angiogenesis via interacting with YBX1 in breast cancer. Cell Death and Disease, 2021, 12, 670.	6.3	26
5	Evaluation of Carbon Nanoparticle Suspension and Methylene Blue Localization for Preoperative Localization of Nonpalpable Breast Lesions: A Comparative Study. Frontiers in Surgery, 2021, 8, 757694.	1.4	6
6	Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Seminars in Cancer Biology, 2020, 60, 14-27.	9.6	460
7	Galactogram Grading System for Identifying Breast Cancer With Nipple Discharge. Clinical Breast Cancer, 2020, 20, e214-e219.	2.4	1
8	Impact of histotypes on preferential organâ€specific metastasis in tripleâ€negative breast cancer. Cancer Medicine, 2020, 9, 872-881.	2.8	13
9	Special subtypes with favorable prognosis in breast cancer: A registry-based cohort study and network meta-analysis. Cancer Treatment Reviews, 2020, 91, 102108.	7.7	11
10	Identification of DGUOK-AS1 as a Prognostic Factor in Breast Cancer by Bioinformatics Analysis. Frontiers in Oncology, 2020, 10, 1092.	2.8	12
11	LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cellular Signalling, 2020, 68, 109536.	3.6	35
12	Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097560.	3.2	3
13	Identification and preservation of stained nonâ€sentinel lymph nodes in breast cancer. Oncology Letters, 2020, 20, 1-1.	1.8	7
14	Clinicopathological features of granulomatous lobular mastitis and mammary duct ectasia. Oncology Letters, 2020, 19, 840-848.	1.8	14
15	SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death and Differentiation, 2019, 26, 843-859.	11.2	130
16	EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nature Communications, 2019, 10, 5033.	12.8	42
17	Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC. Scientific Reports, 2019, 9, 236.	3.3	29
18	Enlarged paraâ€sentinel lymph node dissection is not necessary in breast cancer patients undergoing sentinel lymph node biopsy. Breast Journal, 2019, 25, 1025-1028.	1.0	0

#	Article	IF	Citations
19	Relationship between Upper Extremity Lymphatic Drainage and Sentinel Lymph Nodes in Patients with Breast Cancer. Journal of Oncology, 2019, 2019, 1-7.	1.3	12
20	Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma. Journal of Clinical Pathology, 2019, 72, 418-424.	2.0	37
21	Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma. Frontiers in Genetics, 2019, 10, 278.	2.3	49
22	Epigenetic Regulation of NAMPT by NAMPT-ASDrives Metastatic Progression in Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 3347-3359.	0.9	103
23	Individualized Prediction of Survival Benefit from Postmastectomy Radiotherapy for Patients with Breast Cancer with One to Three Positive Axillary Lymph Nodes. Oncologist, 2019, 24, e1286-e1293.	3.7	7
24	Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biology and Therapy, 2018, 19, 120-131.	3.4	62
25	Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis. Clinical Breast Cancer, 2018, 18, 1-8.	2.4	61
26	Internal Mammary Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer. Journal of Breast Cancer, 2018, 21, 442.	1.9	8
27	Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells. Biomedicine and Pharmacotherapy, 2018, 107, 117-128.	5.6	33
28	CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biology, 2018, 16, e2005869.	5.6	60
29	53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells. Oncology Letters, 2018, 15, 9917-9922.	1.8	7
30	The oncogenic potentials and diagnostic significance of long nonâ€coding RNA LINC00310 in breast cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 4486-4495.	3.6	21
31	Cepharanthine Induces Autophagy, Apoptosis and Cell Cycle Arrest in Breast Cancer Cells. Cellular Physiology and Biochemistry, 2017, 41, 1633-1648.	1.6	63
32	Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nature Cell Biology, 2017, 19, 1274-1285.	10.3	218
33	Huaier extract restrains the proliferative potential of endocrine-resistant breast cancer cells through increased ATM by suppressing miR-203. Scientific Reports, 2017, 7, 7313.	3.3	20
34	Huaier Extract Inhibits Breast Cancer Progression Through a LncRNA-H19/MiR-675-5p Pathway. Cellular Physiology and Biochemistry, 2017, 44, 581-593.	1.6	45
35	The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis. BMC Cancer, 2017, 17, 839.	2.6	30
36	Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells. International Journal of Oncology, 2017, 51, 1320-1330.	3.3	5

#	Article	IF	Citations
37	Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database. Oncotarget, 2017, 8, 24579-24592.	1.8	28
38	Huaier aqueous extract protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NLRP3 inflammasome activation. Oncotarget, 2017, 8, 32937-32945.	1.8	19
39	Precise intraoperative sentinel lymph node biopsies guided by lymphatic drainage in breast cancer. Oncotarget, 2017, 8, 63064-63072.	1.8	9
40	Development and validation of a surgical-pathologic staging and scoring system for cervical cancer. Oncotarget, 2016, 7, 21054-21063.	1.8	7
41	rs621554 single nucleotide polymorphism of DLC1 is associated with breast cancer susceptibility and prognosis. Molecular Medicine Reports, 2016, 13, 4095-4100.	2.4	3
42	Periareolar incision for the management of benign breast tumors. Oncology Letters, 2016, 12, 3259-3263.	1.8	9
43	Radiosensitization effect of Huaier on breast cancer cells. Oncology Reports, 2016, 35, 2843-2850.	2.6	22
44	Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma. Oncology Letters, 2016, 12, 1448-1454.	1.8	2
45	miR-409-3p suppresses breast cancer cell growth and invasion by targeting Akt1. Biochemical and Biophysical Research Communications, 2016, 469, 189-195.	2.1	64
46	53 BP 1 suppresses epithelialâ€“mesenchymal transition by downregulating ZEB 1 through micro RNA â€200b/429 in breast cancer. Cancer Science, 2015, 106, 982-989.	3.9	28
47	Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells. International Journal of Oncology, 2015, 46, 2047-2056.	3.3	16
48	Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system. International Journal of Oncology, 2015, 47, 1070-1076.	3.3	8
49	Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK/p38 pathway. International Journal of Oncology, 2015, 47, 1054-1060.	3.3	27
50	Knockdown of metadherin inhibits angiogenesis in breast cancer. International Journal of Oncology, 2015, 46, 2459-2466.	3.3	17
51	Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stemâ€“like Cell Traits in Breast Cancer. Cancer Research, 2015, 75, 3672-3680.	0.9	76
52	The CUL4B/AKT/Î²-Catenin Axis Restricts the Accumulation of Myeloid-Derived Suppressor Cells to Prohibit the Establishment of a Tumor-Permissive Microenvironment. Cancer Research, 2015, 75, 5070-5083.	0.9	42
53	JAM3methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix. Oncotarget, 2015, 6, 44373-44387.	1.8	27
54	Trail Resistance Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness by Suppressing PTEN via miR-221 in Breast Cancer. PLoS ONE, 2014, 9, e99067.	2.5	45

#	Article	IF	Citations
55	A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis. Gene, 2014, 535, 170-176.	2.2	10
56	MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget, 2014, 5, 9106-9117.	1.8	58
57	miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget, 2014, 5, 10816-10829.	1.8	91
58	A multiplex methylation-specific PCR assay for detection of early-stage ovarian cancer using cell-free serum DNA.. Journal of Clinical Oncology, 2013, 31, 5535-5535.	1.6	0
59	Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. Journal of Clinical Oncology, 2006, 24, 5652-5657.	1.6	956
60	Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncology Reports, 2003, 10, 121-5.	2.6	31
61	Retinoid, Retinoic Acid Receptor Î² and Breast Cancer. Breast Cancer Research and Treatment, 2002, 76, 167-173.	2.5	51
62	The Fragile Histidine Triad gene and breast cancer. Medical Science Monitor, 2002, 8, RA140-4.	1.1	5
63	Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clinical Cancer Research, 2002, 8, 2890-3.	7.0	49
64	BRCA1 in non-inherited breast carcinomas (Review). Oncology Reports, 2002, 9, 1329-33.	2.6	14
65	Loss of Msh2 is not associated with FHIT deletion in breast carcinomas. Anticancer Research, 2002, 22, 2591-5.	1.1	1
66	Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer, 2001, 92, 54-60.	4.1	81